IL145310A0 - Vascular adhesion molecules and modulation of their function - Google Patents

Vascular adhesion molecules and modulation of their function

Info

Publication number
IL145310A0
IL145310A0 IL14531000A IL14531000A IL145310A0 IL 145310 A0 IL145310 A0 IL 145310A0 IL 14531000 A IL14531000 A IL 14531000A IL 14531000 A IL14531000 A IL 14531000A IL 145310 A0 IL145310 A0 IL 145310A0
Authority
IL
Israel
Prior art keywords
adhesion molecules
modulation
function
vascular adhesion
cram
Prior art date
Application number
IL14531000A
Other languages
English (en)
Original Assignee
Rmf Dictagene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene Sa filed Critical Rmf Dictagene Sa
Publication of IL145310A0 publication Critical patent/IL145310A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
IL14531000A 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function IL145310A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (1)

Publication Number Publication Date
IL145310A0 true IL145310A0 (en) 2003-01-12

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14531000A IL145310A0 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Country Status (23)

Country Link
US (3) US7393651B2 (ru)
EP (2) EP2292761A1 (ru)
JP (2) JP4836329B2 (ru)
CN (2) CN1637019A (ru)
AT (1) ATE500328T1 (ru)
AU (1) AU782139B2 (ru)
BR (1) BR0008915A (ru)
CA (1) CA2362896C (ru)
CZ (1) CZ303128B6 (ru)
DE (1) DE60045681D1 (ru)
EE (1) EE05497B1 (ru)
ES (1) ES2361905T3 (ru)
HK (1) HK1044169A1 (ru)
HU (1) HU229376B1 (ru)
IL (1) IL145310A0 (ru)
IS (1) IS2819B (ru)
MX (1) MXPA01009110A (ru)
NO (1) NO333085B1 (ru)
NZ (1) NZ514091A (ru)
PL (1) PL207994B1 (ru)
RU (1) RU2244748C2 (ru)
WO (1) WO2000053749A2 (ru)
ZA (1) ZA200107283B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
CZ303128B6 (cs) * 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
WO2007056227A2 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
CA2663243A1 (en) 2006-09-28 2008-04-03 Merck Serono S.A. Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
LT2190991T (lt) * 2007-08-06 2020-02-10 Noxxon Pharma Ag Sdf-1 surišančios nukleorūgštys ir jų panaudojimas
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2000036102A2 (en) * 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
WO1998040483A2 (en) * 1997-03-14 1998-09-17 Human Genome Sciences, Inc. 28 human secreted proteins
EP0970111A2 (en) * 1997-03-21 2000-01-12 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DK1000149T3 (da) 1997-08-01 2007-09-10 Serono Genetics Inst Sa 5'-EST'ere til udskilte proteiner identificeret fra hjernevæv
US20030092002A1 (en) * 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) * 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
CZ303128B6 (cs) * 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
CA2362896A1 (en) 2000-09-14
ZA200107283B (en) 2002-12-24
CZ20013267A3 (cs) 2002-02-13
US7393651B2 (en) 2008-07-01
HUP0200606A2 (en) 2002-06-29
EE200100472A (et) 2002-12-16
CN100469878C (zh) 2009-03-18
CN1355843A (zh) 2002-06-26
HU229376B1 (en) 2013-11-28
US20100267649A1 (en) 2010-10-21
EP1163337B1 (en) 2011-03-02
BR0008915A (pt) 2002-04-09
NO20014417L (no) 2001-11-12
CN1637019A (zh) 2005-07-13
US7670826B2 (en) 2010-03-02
WO2000053749A3 (en) 2000-12-14
JP2010233572A (ja) 2010-10-21
MXPA01009110A (es) 2002-08-20
ATE500328T1 (de) 2011-03-15
AU4105100A (en) 2000-09-28
JP2002537837A (ja) 2002-11-12
HUP0200606A3 (en) 2004-11-29
EP2292761A1 (en) 2011-03-09
NZ514091A (en) 2004-01-30
AU782139B2 (en) 2005-07-07
US20080274970A1 (en) 2008-11-06
ES2361905T3 (es) 2011-06-24
EE05497B1 (et) 2011-12-15
EP1163337A2 (en) 2001-12-19
NO333085B1 (no) 2013-02-25
RU2244748C2 (ru) 2005-01-20
NO20014417D0 (no) 2001-09-11
IS2819B (is) 2012-12-15
PL350417A1 (en) 2002-12-16
DE60045681D1 (de) 2011-04-14
HK1044169A1 (en) 2002-10-11
JP4836329B2 (ja) 2011-12-14
US8143056B2 (en) 2012-03-27
CZ303128B6 (cs) 2012-04-18
CA2362896C (en) 2012-07-31
US20050266426A1 (en) 2005-12-01
IS6072A (is) 2001-09-10
WO2000053749A2 (en) 2000-09-14
PL207994B1 (pl) 2011-02-28

Similar Documents

Publication Publication Date Title
PL350417A1 (en) Vascular adhesion molecules and modulation of their function
PT1132403E (pt) Peptidos inibidores de tgf g beta1
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
ATE516297T1 (de) Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
DK0770089T3 (da) Vækstdifferentieringsfaktor-12
BR9007115A (pt) Novo trombolitico
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
DE69832197D1 (de) Rantes mutanten und deren therapeutische verwendungen
EP0870036A4 (en) MAMMALIAN SYNTHETIC ALPHA-N-ACETYLGLUCOSAMINIDASE AND GENE SEQUENCES ENCODING IT
BG105682A (en) Bone stimulating factor
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
WO1999030670A3 (en) Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
EP0832109A4 (en) FIBROPLAST GROWTH FACTOR APPROVED FACTOR-2 AND METHODS OF USE
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
WO1999046381A3 (en) Human fgf gene and gene expression products
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus